Prevention of endometrial hyperplasia and its transition to endometrial cancer with SHETA2 POP 6/1/2017 - 5/31/2019
Ended Awarded Last action
- Contract number
- HHSN26100008
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $709,326
Award facts
- Opportunity
-
- N01CN5500347 Solicitation number
- Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Sep 25, 2015
- Preclinical PREVENT Cancer Program for Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Jan 5, 2015
- Contract value 100% obligated
- $709,326.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Oklahoma City, OK 73104, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$4,662 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $713,988 |
About this award
The National Cancer Institute issued a delivery order to the University of Oklahoma's Health Sciences Center on May 19, 2017, under the PREVENT Cancer Program IDIQ for preclinical prevention of endometrial hyperplasia and its transition to endometrial cancer using SHETA2, with a ceiling value of $709,326 and cost-no-fee pricing.
The PREVENT Cancer Program is a National Cancer Institute IDIQ supporting cancer prevention drug development through multiple delivery orders. Place of performance is Oklahoma City, OK. The order ultimate completion date is June 14, 2021. The project scope encompasses preclinical efficacy studies and intermediate endpoint biomarkers in two phases: the first running June 1, 2017 through May 31, 2019, and the second extending June 15, 2017 through June 14, 2021.
Service Contract Inventory reporting shows government-invoiced labor of $63 thousand in FY2020 and $32 thousand in FY2021, with the prime self-performing all reported hours and no subcontractors reported.
Quick answers
Who was awarded contract HHSN26100008?
HHSN26100008 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on May 19, 2017.
How much is contract HHSN26100008 worth?
The government has obligated $709,326 on HHSN26100008.
Is contract HHSN26100008 an order under another contract?
Yes. HHSN26100008 is a delivery order under HHSN261201500038I, an indefinite delivery contract, on PREVENT Cancer Program (PREVENT).
Was contract HHSN26100008 competed?
The extent of competition for HHSN26100008 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award